Linvoseltamab Earns FDA Priority Review for Multiple Myeloma
Linvoseltamab shows promise for patients with heavily pretreated multiple myeloma, achieving a 71% overall response rate in a phase 1/2 trial.
Advancing Myeloma Treatment With Blood-Based MRD Testing
In this episode of Targeted Talks, Ben Derman, MD, dissects the latest advancements in myeloma treatment, focusing on the role of ClonoSeq and minimal residual disease monitoring.
Targeting GPRC5D Impacts Survival of Heavily Pretreated Patients With Relapsed/Refractory Multiple Myeloma
At a live virtual event, Jack Khouri, MD, discussed how treatment options for patients with relapsed/refractory multiple myeloma have evolved with the use of bispecific antibodies giving physicians the opportunity to target BCMA and GPRC5D on the plasma cell.
In R/R Myeloma, Belantamab Mafodotin/BorDex Outperforms Standard Treatment
According to an interim analysis of the DREAMM-7 trial, belantamab mafodotin, bortezomib, and dexamethasone achieved a statistically significant and clinically meaningful improvement in progression-free survival among patients with multiple myeloma.
Sborov Reviews How Isatuximab Fits Into R/R Multiple Myeloma
In the second article of a 2-part series, Douglas Sborov, MD, discusses the toxicities seen with isatuximab and how this therapy can impact patients in rural areas relying on community center treatment.
FDA ODAC to Review Ide-Cel Data in Multiple Myeloma
The FDA’s Oncologic Drug Advisory Committee will be held on March 15, 2024, to review data pertaining to the supplemental biologics license application of ide-cel in relapsed or refractory multiple myeloma.
2 Commerce Drive Cranbury, NJ 08512